Pfizer

Pfizer Inc. maintained sales forecasts for the company’s pandemic products on May 3 after a series of hikes to revenue projections for its COVID-19 vaccine in 2021, in a sign that dizzying growth has slowed.

China’s commercial capital of Shanghai was dealt a blow on May 2 as authorities reported 58 new COVID-19 cases outside areas under strict lockdown, while Beijing pressed on with testing millions of people on a May Day holiday few were celebrating.

Two new sublineages of the Omicron coronavirus variant can dodge antibodies from earlier infection well enough to trigger a new wave, but are far less able to thrive in the blood of people vaccinated against COVID-19, South African scientists found.

Moderna Inc. asked U.S. regulators to authorize the company’s COVID-19 vaccine for children under the age of 6, which would make it the first shot against the coronavirus available for those under 5-years-old.

Following the record surge in COVID-19 cases during the Omicron-driven wave, some 58 percent of the U.S. population overall and more than 75 percent of younger children have been infected with the coronavirus since the start of the pandemic, according to a U.S. nationwide blood survey released on April 26.

Pfizer Inc. and the company’s partner BioNTech SE said on April 26 that they had submitted an application to the U.S. health regulator for the authorization of a booster dose of their COVID-19 vaccine for children aged 5 to 11 years.

CureVac and GSK’s second-generation vaccine candidate targeting two recent COVID-19 variants has been shown to be highly effective in preclinical studies on mice, CureVac said, as the biotech firm seeks to catch up with rivals’ development work.

Moderna plans to submit an application to the U.S. health regulator for emergency use authorization (EUA) of the company’s COVID-19 vaccine among kids between the ages of six months to five years by the end of the month, a company spokesperson said.

COVID-19 cases and deaths are declining in the Americas, the Pan American Health Organization (PAHO) said on April 20, with infections last week having dropped 2.3 percent and deaths falling 15.2 percent from the prior week. The broad trend comes even as cases have scaled up in North America with an 11.2 percent increase last week, the organization said.

The BA.2 sub-variant of Omicron and its sublineage BA.2.12.1 is estimated to make up more than 90 percent of the coronavirus variants in the United States as of April 16, the U.S. Centers for Disease Control and Prevention (CDC) said on April 19.